Clear ×
MYRIAD GENETICS INC MYGN

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 16, 2026 8-K 1 signal fired
Core
Management Exodus
Jul 31, 2026 10-Q 32 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Goodwill Impairment Impairment Charge Breakdown Covenant Compliance Affirmation Effective Tax Rate Reconciliation Quarterly Tax Provision Benefit Disclosure Equity Plan Board Approval Conditional On Shareholder Vote Share Repurchase Activity Disclosed Equity Plan Share Reserve Disclosure Libor Based Term Loan Pricing Event Of Default Defined Ai Diagnostics Investment Liquidity Position Snapshot Disclosed Weighted Average Interest Rate Disclosed
Healthcare
Reimbursement Improving
Jul 30, 2026 8-K 13 signals fired
Other
Net Loss Reported Ai Diagnostics Investment Gross Margin Comparison Disclosed Interim Data Positive Publication Positive Kol Endorsement Liquidity Position Snapshot Disclosed Goodwill Impairment Patient Retention High
Core
Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned
Healthcare
Utilization Improving
Jun 23, 2026 8-K 1 signal fired
Core
Management Exodus
Jun 4, 2026 8-K 3 signals fired
Other
Auditor Appointment Ratification Classified Board Director Election Equity Plan Share Reserve Disclosure
May 6, 2026 10-Q 32 signals fired · top 15
Other
Goodwill Impairment Use Of Proceeds Disclosure Reimbursement Price Pressure Risk Effective Tax Rate Reconciliation Codm Segment Reporting Disclosure Covenant Compliance Affirmation Equity Plan Board Approval Conditional On Shareholder Vote Share Repurchase Activity Disclosed Libor Based Term Loan Pricing Equity Plan Share Reserve Disclosure Impairment Charge Breakdown Advertising Cost Disclosure Deferred Tax Asset Valuation Disclosure Quarterly Tax Provision Benefit Disclosure
Healthcare
Reimbursement Improving
May 5, 2026 8-K 15 signals fired
Biotech Risk
Accelerated Approval
Other
Net Loss Reported Ai Diagnostics Investment Gross Margin Comparison Disclosed Liquidity Position Snapshot Disclosed Ce Mark Received Interim Data Positive Kol Endorsement
Core
Clinical Trial Result Indication Expansion
Healthcare
Reimbursement Improving Same Facility Growth Volume Inflecting
SaaS
Billings Acceleration Same Client Revenue Growing